|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University Hospital Muenster |
| Information provided by: | University Hospital Muenster |
| ClinicalTrials.gov Identifier: | NCT00111371 |
Purpose
This study aims to determine whether levodopa, in combination with a high frequency training of (grammatical) rules, is effective in boosting learning success in healthy subjects and whether this kind of training in combination with levodopa improves reading and spelling abilities of patients with dyslexia.
| Condition | Intervention | Phase |
|
Dyslexia |
Drug: Levodopa |
Phase IV |
| MedlinePlus related topics: | Memory |
| ChemIDplus related topics: | Dopamine Dopamine hydrochloride Levodopa |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia) |
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2005 |
| Estimated Study Completion Date: | October 2007 |
Prior work by our group shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind trial, we probe whether daily administration of levodopa, coupled with a training of grammatical rules, improves the training success in healthy adults as compared to placebo administration. In the second step of this study, patients with dyslexia will be trained with the identical protocol. We postulate that the combination of intensive training in language rules and levodopa improves the reading, writing, and spelling abilities of patients with dyslexia.
Eligibility
| Ages Eligible for Study: | 18 Years to 35 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Stefan Knecht, MD | +49-251-83 ext 48195 | knecht@uni-muenster.de |
| Germany, North-Rhine Westphalia | |||||
| Dept. of Neurology, University Hospital of Muenster | Recruiting | ||||
| Muenster, North-Rhine Westphalia, Germany, 48129 | |||||
| Contact: Stefan Knecht, Prof. Dr. +49-251-83 ext 48195 knecht@uni-muenster.de | |||||
| Principal Investigator: Stefan Knecht, M.D. | |||||
| University Hospital Muenster |
| Principal Investigator: | Stefan Knecht, Prof. Dr. | Dept. of Neurology, Universityclinic of Muenster |
More Information
| Study ID Numbers: | LL-001; Project on Dyslexia |
| First Received: | May 19, 2005 |
| Last Updated: | April 18, 2007 |
| ClinicalTrials.gov Identifier: | NCT00111371 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|
|